Epstein-Barr virus (EBV), also known as human herpes virus-4, belongs to the γ-subfamily of herpes viruses. Nearly 90 to 95% of the world's adult population is an asymptomatic carrier of EBV..
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5005/jp-journals-10024-2028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Peri-Implant Epstein-Barr Virus (+) Mucocutaneous Ulcer in an Immunocompetent Patient: Case Report and Review of the Literature.
Clin Implant Dent Relat Res
February 2025
Department of Stomatology, Research Group GIU21/042, University of the Basque Country/EHU, Leioa, Spain.
Epstein-Barr virus (+) mucocutaneous ulcer (EBVMCU) is an uncommon benign lymphoproliferative lesion that develops in immunocompromised patients. We present a special case of EBVMCU located in the peri-implant mucosa and we review the oral cases published to date. An 88-year-old man with no medical history of interest was attended in the dental clinic due to an ulcerated tumor located in the peri-implant mucosa.
View Article and Find Full Text PDFClinical imaging and pathology analysis of Epstein-Barr virus-associated monomorphic lymphoproliferative disease after liver transplantation in children-a retrospective case series.
Transl Pediatr
December 2024
Department of Hematology, Chongqing Medical University Affiliated Children's Hospital, Chongqing, China.
Background: Post-transplant lymphoproliferative disease (PTLD) is a significant complication that can arise following solid organ transplantation or hematopoietic stem cell transplantation. It encompasses a spectrum of lymphoproliferative lesions, ranging from benign reactive hyperplasia to malignant tumors, and is among the most severe complications following liver transplantation in children. It is essential for clinicians to gain a comprehensive understanding of the prevention, clinical manifestations, early diagnosis, and treatment strategies for PTLD in order to reduce mortality rates.
View Article and Find Full Text PDFGlycoprotein 350-targeted chimeric antigen receptor T-cell therapy for nonneoplastic chronic active Epstein-Barr virus infection: a case report.
Transl Pediatr
December 2024
Department of Infectious Diseases, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Chronic active Epstein-Barr virus (CAEBV) infection is a rare disease in which the Epstein-Barr virus (EBV) persists and replicates, causing chronic symptoms and fatal complications. The treatment of CAEBV is still evolving. Our case report showed a new therapy for CAEBV.
View Article and Find Full Text PDFEnhanced pathogen identification among patients with clinically suspected meningitis.
S Afr J Infect Dis
December 2024
Division of Medical Microbiology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Background: Delayed or incorrect treatment of meningitis may result in adverse patient outcomes. However, laboratory testing in resource-limited settings is often limited to conventional diagnostic methods. We explored the utility of syndromic molecular assays for diagnosis.
View Article and Find Full Text PDFSpatial and Temporal Tumor Heterogeneity in Gastric Cancer: Discordance of Predictive Biomarkers.
J Gastric Cancer
January 2025
Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Gastric cancer (GC) is a highly heterogeneous disease that varies in both histological presentation and genetic characteristics. Recent advances in the treatment of metastatic and unresectable GC have made several biomarker tests essential for patient management. Predictive biomarkers such as human epidermal growth factor receptor 2 (HER2), programmed death-ligand 1 (PD-L1), mismatch-repair (MMR) proteins, claudin 18.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!